Organization and Running of the First Comprehensive Hereditary Cancer Clinic in India

Hereditary Cancer in Clinical Practice

S Vijaya⁵  SG Ramanan¹  V Mahajan²  V Sridevi²  E Vidubala⁴  N Soumittra³  T Rajkumar³ 

[1] Dept. of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai - 600020, India;Dept. of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai - 600020, India;Dept. of Molecular Oncology, Cancer Institute (WIA), Adyar, Chennai - 600020, India;Dept. of Preventive Oncology, Cancer Institute (WIA), Adyar, Chennai - 600020, India;Dept. of Radiation Oncology, Cancer Institute (WIA), Adyar, Chennai - 600020, India

关键词: social issues;    dHPLC;    mutation analysis;    India;    hereditary cancers;    hereditary cancer clinic;   

Others  :  812126
DOI  :  10.1186/1897-4287-3-4-165

 received in 2005-10-28, accepted in 2005-11-01,  发布年份 2005

【 摘 要 】

Hereditary cancers are thought to account for around 5% of cancers, particularly breast/ovarian and colorectal cancers. In India there is a paucity of data on hereditary cancers and the mutations in some of the common genes linked to hereditary cancers, such as BRCA1, BRCA2, hMSH2 and hMLH1. The country's first comprehensive hereditary cancer clinic was established in February 2002. The article describes the organization and running of the Clinic. It also discusses some of the social issues relevant to the given population in running the Hereditary Cancer Clinic.

   

【 参考文献 】

• [1]Shanta V, Swaminathan R: Cancer incidence and mortality in Chennai, India 2002. National Cancer registry program, Cancer Institute (WIA), Chennai; 2005.
• [2]Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancerbase No. 5, version 2.0, IARC press, Lyon; 2004.
• [3]Saxena S, Szabo CI, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE, Bhatanager D: BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat 2002, 20:473-474.
• [4]Kumar BV, Lakhotia S, Ankathil R, Madhavan J, Jayaprakash PG, Nair MK, Somasundaram K: Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol Ther 2002, 1:18-21.
• [5]Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V, Shanta V: BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev 2003, 4:203-208.
• [6]Rajkumar T, Soumittra N, Pandey D, Nancy KN, Mahajan V, Majhi U: Mutation analysis of hMSH2 and hMLH1 in colorectal cancer patients in India. Genet Test 2004, 8:157-162.
• [7]Gould RL, Lynch HT, Smith RA, McCarthy JF: Cancer and Genetics. Answering your patients questions. A manual for clinicians and their patients. American Cancer Society and PRR Inc 1998, Chapter 6:59-65.
• [8]Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997, 89:1758-1762.
• [9]Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al.: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996, 276:1575-1579.
• [10]Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969, 71:747-752.
• [11]Eeles RA: Germline mutations in the TP53 gene. Cancer Surv 1995, 25:101-124.
• [12]Padberg BC, Schroder S, Jochum W, Kastendieck H, Roth J, Heitz PU, Komminoth P: Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am J Pathol 1995, 147:1600-1607.
• [13]Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA: p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994, 70:496-500.
• [14]Verselis SJ, Rheinwald JG, Fraumeni JF Jr, Li FP: Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene 2000, 19:4230-4235.